ACRS three-lens brief
Evidence-based stock research on ACRS. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Analyst mean target $10.18 — 85% above current (11 analysts). · Trading >3% below the 50-day MA — short-term weakness.
- Trading >3% below the 50-day MA — short-term weakness.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $10.18 — 85% above current (11 analysts).
- Negative free cash flow last quarterly (-$41.97M).
ACRS closed at $5.50 (-0.99%) as of 2026-09-11. Market cap: $810.33M. Price is below the 50-day MA and above the 200-day MA. Positives: analyst mean target $10.18 — 85% above current (11 analysts).. Concerns: trading >3% below the 50-day MA — short-term weakness.; currently unprofitable on a trailing basis — no P/E multiple available.. Last quarter: Revenue $1.63M, net income -$21.50M, free cash flow -$41.97M.
Why three lenses on ACRS, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ACRSacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ACRS" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ACRS brief"></iframe>